

- Aging, world demography of (*Cont.*):  
 population aging trends, 70–71, 70f, 71f  
 population size projections, 93e–2–3
- Agitation, in terminally ill patient, 69t
- Agonogenic myeloid metaplasia. *See* Primary myelofibrosis
- Agnosia, visual object, 182, 2575
- Agonal gasps, 1775
- Agoraphobia, 151, 2709
- Agouti-related peptide (AgRP), 415e–2, 415e–4, 415e–4f, 415e–4t
- Agrammatism, 178
- Agranulocytosis, 237
- Agraphesthesia, 160
- Agraphia, 177
- agr* gene, 955
- Agurin, 2702
- Agrobacterium* spp., 487
- AH amyloidosis. *See* Amyloidosis
- AH interval, 1474, 1474f
- Ahlstrom's syndrome, 415e–5t
- AHO. *See* Albright's hereditary osteodystrophy (AHO)
- aHUS (atypical hemolytic uremic syndrome), 657
- AIDP (acute inflammatory demyelinating polyneuropathy), 2695, 2695t, 2696t
- AIDS. *See also* HIV infection  
 deaths from, 16e–1f, 1224f, 1227f  
 definition of, 1215–1216, 1216t, 1217t  
 incidence of, 1223–1225, 1227f
- AIDS dementia complex (HIV-associated dementia), 1263, 1264t, 1265f
- AIM2 inflammasome, 145e–8f
- AIN. *See* Acute interstitial nephritis (AIN)
- Ainhum, 2750
- AION (anterior ischemic optic neuropathy), 202, 202f
- AIP. *See* Acute intermittent porphyria (AIP)
- AIP gene mutations, 2340
- Air-conditioner lung, 1681t
- Air-conduction threshold, 222
- AIRE gene mutations, 377e–2, 1343, 2113, 2323, 2345, 2483
- Air flow  
 in COPD, 1701–1702, 1704t  
 in lung, 306e–1–2, 306e–2f, 306e–3f, 306e–6
- Air hunger, 47e–1, 47e–1t
- Air pollution  
 asthma and, 1670, 1671  
 COPD and, 1703  
 lung disease and, 1693
- Air travel  
 fitness for, 794, 799  
 in pregnancy, 797–798  
 venous thrombosis risk in, 744
- Airway, rewarming of, 478e–3
- Airway clearance, in cardiopulmonary resuscitation, 1768
- Airway hyperresponsiveness  
 in asthma, 1672, 1675  
 in COPD, 1702–1703  
 in sarcoidosis, 2207
- Airway obstruction  
 in cancer, 1794, 1794f  
 in deep neck infections, 235  
 dyspnea in, 47e–1t
- Airway pressure release ventilation, 1742
- Airway remodeling, in asthma, 1675
- Airway resistance ( $R_{aw}$ )  
 increased, dyspnea in, 47e–2  
 measurement of, 306e–6  
 in obstructive respiratory disorders, 306e–5f  
 in restrictive respiratory disorders, 306e–5f
- AIS. *See* Androgen insensitivity syndrome (AIS)
- Akathisia, 2624, 2716, 2722
- AK (adenylate kinase) deficiency, 654t
- AKI. *See* Acute kidney injury (AKI)
- Akinetic mutism, 1771
- AKR1C2 gene mutations, 2353, 2354t
- AKT gene mutations  
 cancers associated with, 101e–2t  
 in Cowden's syndrome, 2344  
 in lung cancer, 507t, 509f  
 in melanoma, 496
- AKT pathway, in melanoma, 496, 496f
- ALA (5-aminolevulinic acid), 386
- ALA (5-aminolevulinic acid) dehydrase, 2523t, 2524
- ALA (5-aminolevulinic acid)-dehydratase deficient porphyria, 2521, 2522f, 2522t, 2523t, 2526
- ALA (5-aminolevulinic acid) synthase, 2522, 2523t, 2524–2525
- ALAD gene, 2523t
- AL amyloidosis, 720. *See also* Amyloidosis  
 clinical features of, 721, 721f, 2642  
 diagnosis of, 365, 720f, 721, 722f, 1845  
 differential diagnosis of, 1835t  
 etiology and incidence of, 720–722  
 pathogenesis of, 1845  
 treatment of, 721–723, 1845
- Alanine aminotransferase (ALT)  
 in acute viral hepatitis, 2008f, 2010f, 2016  
 in alcoholic liver disease, 2053, 2053t  
 in autoimmune hepatitis, 2050  
 in chronic HBV infection, 2033  
 in liver function evaluation, 1997, 1998t  
 in SLE, 2131
- ALARA principle, 263e–4
- ALAS genes, 2523t, 2524, 2526
- Albendazole  
 action of, 246e–1  
 adverse effects of, 246e–1, 246e–3t  
 for ascariasis, 1413–1414  
 for capillariasis, 1417  
 for cutaneous larva migrans, 1411t  
 for cysticercosis, 1432  
 drug interactions of, 246e–1, 246e–3t  
 for echinococcosis, 1433, 1434  
 for enterobiasis, 1416  
 for *Giardia* infections, 1406  
 for gnathostomiasis, 1411t  
 for hookworm infections, 1415  
 indications for, 246e–3t  
 for loiasis, 1422  
 for lymphatic filariasis, 1419  
 for neurocysticercosis, 903  
 pharmacology of, 246e–1  
 in pregnancy and lactation, 246e–3t  
 for strongyloidiasis, 1416  
 for trichinellosis, 1411t  
 for trichuriasis, 1416  
 for visceral larva migrans, 1411t
- Albers-Schonberg disease, 426e–4
- Albinism  
 ocular, 434e–2t  
 oculocutaneous, 357, 357t, 434e–2t  
 skin cancer in, 500
- Albright's hereditary osteodystrophy (AHO)  
 genetic considerations in, 430, 437, 2284t, 2486, 2486t  
 hypothyroidism in, 2284t
- Albumin  
 serum  
 causes of abnormal values, 464t  
 in edema, 253  
 in hypercalcemia, 314  
 in liver function evaluation, 1997–1998  
 in nutritional assessment, 462, 464t  
 urinary, 293, 1813. *See also* Microalbuminuria
- Albuterol, 312, 473e–8t
- Alcaligenes xylosoxidans*. *See* *Achromobacter xylosoxidans*
- Alcohol, 2723. *See also* Alcohol use; Alcohol use disorder (alcoholism)  
 absorption of, 2058, 2723  
 acetaminophen toxicity and, 44  
 action of, 444e–4, 465e–5t  
 behavioral effects of, 2724, 2724t, 2765t  
 drug interactions of, 939t  
 metabolism of, 2723, 2723f  
 pharmacology of, 2723–2724  
 tolerance of, 2724
- Alcohol dehydrogenase (ADH), 2058
- Alcohol hand rub, 913
- Alcoholic ketoacidosis, 299, 318–319
- Alcoholic liver disease, 2052  
 acetaminophen hepatotoxicity and, 366e–4f  
 cirrhosis, 2058–2059, 2058f, 2075  
 clinical features of, 2053, 2058–2059  
 diagnosis of, 1998t, 2053, 2053t, 2059, 2517t  
 etiology of, 2052  
 global considerations in, 2052  
 pathogenesis of, 2052, 2058, 2725  
 pathology of, 2053  
 prognosis of, 2053  
 risk factors for, 1991–1992, 1992t, 2052, 2052t  
 treatment of, 2053, 2059  
 alcohol abstinence, 1995  
 algorithm for, 2054f  
 glucocorticoids, 2053, 2054f  
 liver transplantation, 2068, 2075
- Alcohol septal ablation, 1569
- Alcohol use  
 breast cancer and, 524, 2725  
 cardiovascular effects of, 2725  
 esophageal cancer and, 532–533, 2725  
 genitourinary effects of, 2725  
 head and neck cancer and, 502, 2725  
 hematopoietic effects of, 2725  
 hepatocellular carcinoma and, 545, 545t  
 hypertension and, 1622–1623, 1622t  
 hyperuricemia and, 431e–3  
 lipoprotein disorders and, 2438  
 liver disease and. *See* Alcoholic liver disease  
 nervous system effects of, 2724  
 porphyria cutanea tarda and, 2530  
 in pregnancy, 2725  
 prevalence of, 2058  
 sleep disturbances and, 190, 2724  
 testicular dysfunction and, 2365
- Alcohol use disorder (alcoholism), 2726. *See also* Alcohol withdrawal syndrome  
 acetaminophen toxicity in, 44, 2027  
 acute intoxication, 164  
 anemia in, 398  
 cancer risk and, 477t, 2725  
 cardiovascular disease in, 1562, 2725  
 cognitive dysfunction in, 2607, 2724  
 definition of, 2726, 2726t  
 dental disease and, 236  
 diagnosis of, 2725–2726, 2726t  
 epidemiology of, 2726, 2728  
 erectile dysfunction in, 326  
 folate deficiency in, 647  
 gastrointestinal effects of, 277, 2725  
 genetic considerations in, 2726  
 global considerations in, 2728  
 hepatitis in, 283  
 hormonal disturbances in, 2725–2726  
 hypoglycemia in, 2433  
 hyponatremia in, 300  
 hypothermia and, 478e–1  
 involuntary weight loss in, 275  
 lifetime risk for, 2723  
 liver disease in. *See* Alcoholic liver disease  
 myopathy in, 462e–20, 462e–20t, 2725  
 natural history of, 2726  
 nausea and vomiting in, 259  
 nervous system effects of, 2724  
 neuropathy in, 2642, 2724  
 ocular involvement in, 211  
 olfactory/taste dysfunction in, 215  
 palpitations in, 254  
 pancreatic insufficiency in, 269  
 pancreatitis in, 2091, 2725  
 prevalence of, 398, 2058  
 psychiatric comorbidity with, 2724–2725  
 rehabilitation for, 2728  
 screening for, 29t, 1992, 1992t  
 testicular defects in, 2365  
 thiamine deficiency in, 96e–1, 461  
 treatment of, 2726–2728  
 in war veterans, 471e–4, 471e–5t  
 in women, 6e–5